Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas.
BACKGROUND
Hematological abnormalities are common manifestations of advanced HIV-1 infection that could affect the outcomes of highly-active antiretroviral therapy (HAART). Although most HIV-1-infected individuals live in resource-constrained countries, there is little information about the frequency of hematological abnormalities such as anemia, neutropenia, and thrombocytopenia among individuals with advanced HIV-1 disease.


METHODS
This study compared the prevalence of pre-antiretroviral therapy hematological abnormalities among 1571 participants in a randomized trial of antiretroviral efficacy in Africa, Asia, South America, the Caribbean, and the USA. Potential covariates for anemia, neutropenia, and thrombocytopenia were identified in univariate analyses and evaluated in separate multivariable models for each hematological condition.


RESULTS
The frequencies of neutropenia (absolute neutrophil count ≤1.3×10⁹/l), anemia (hemoglobin ≤10g/dl), and thrombocytopenia (platelets ≤125×10⁹/l) at initiation of antiretroviral therapy were 14%, 12%, and 7%, respectively, and varied by country (p<0.0001 for each). In multivariable models, anemia was associated with gender, platelet count, and country; neutropenia was associated with CD4+ lymphocyte and platelet counts; and thrombocytopenia was associated with country, gender, and chronic hepatitis B infection.


CONCLUSIONS
Differences in the frequency of pretreatment hematological abnormalities could have important implications for the choice of antiretroviral regimen in resource-constrained settings.
Firnhaber
Cynthia
C
Department of Medicine/Clinical HIV Research Unit, University of Witwatersrand, Postnet suite 176, Private Bag X2600, Johannesburg 2041, South Africa. cfirnhaber@witshealth.co.za
Smeaton
Laura
L
Saukila
Nasinuku
N
Flanigan
Timothy
T
Gangakhedkar
Raman
R
Kumwenda
Johnstone
J
La Rosa
Alberto
A
Kumarasamy
Nagalingeswaran
N
De Gruttola
Victor
V
Hakim
James Gita
JG
Campbell
Thomas B
TB
D000328:Adult; D000349:Africa / Q000453:epidemiology; D000569:Americas / Q000453:epidemiology; D000740:Anemia / Q000150:complications / Q000453:epidemiology*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D001208:Asia / Q000453:epidemiology; D017691:Caribbean Region / Q000453:epidemiology; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000150:complications / Q000453:epidemiology*; D015995:Prevalence; D013020:South America / Q000453:epidemiology; D013921:Thrombocytopenia / Q000150:complications / Q000453:epidemiology*; D014481:United States / Q000453:epidemiology
D019380:Anti-HIV Agents